This is a working overview of storage stability, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-04-01 and is reviewed periodically as new material appears.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
In any case, suvorexant is a controlled substance in the United States due to concerns about the possibility of misuse. Besides its subjective side effects, suvorexant has been found to cause dose-dependent increases in serum cholesterol levels in clinical trials. These changes in cholesterol levels were +1.2 mg/dL at 10 mg, +2.3 mg/dL at 20 mg, +3.1 mg/dL at 40 mg, and +6.0 mg/dL at 80 mg relative to –3.7 mg/dL for placebo. Although the increases in cholesterol levels with approved doses of suvorexant (10–20 mg) are small, they could be important over a long duration of treatment. Early studies in rodents found that orexins (derived from Greek "orexis" meaning "appetite") stimulate appetite, feeding behavior, and weight gain while orexin receptor antagonists block these effects. However, subsequent animal studies were more mixed, with the effects being limited and depending on the animal strain. In humans, orexin receptor antagonists including suvorexant have not been found to affect body weight in rigorous clinical trials that lasted up to 12 to 14 months.
The tissue is then prepared for viewing under a microscope using either chemical fixation or frozen section. If a large sample is provided e.g. from a surgical procedure then a pathologist looks at the tissue sample and selects the part most likely to yield a useful and accurate diagnosis - this part is removed for examination in a process commonly known as grossing or cut up. Larger samples are cut to correctly situate their anatomical structures in the cassette. Certain specimens (especially biopsies) can undergo agar pre-embedding to assure correct tissue orientation in cassette & then in the block & then on the diagnostic microscopy slide. This is then placed into a plastic cassette for most of the rest of the process.
== Properties == Protolichesterinic acid is a member of the class of chemicals known as lactone fatty acids, a group that includes lichesterinic acid, alloprotolichesterinic acid, nephromopsinic acid, and nephrosterinic acid. In its purified form, protolichesterinic acid is a crystalline solid that forms lustrous plates when recrystallized from benzene or acetic acid at temperatures below 50 °C (122 °F). It has a melting point of 107.5 °C (225.5 °F). The compound exists in both enantiomeric forms, with the (+)-enantiomer showing an optical rotation of [α]D +12° in chloroform and the (-)-enantiomer showing [α]D -12° in chloroform. In ultraviolet–visible spectroscopy, it shows maximum absorption at 218 nm in methanol. Its infrared spectrum (KBr) shows characteristic peaks including those corresponding to carboxylic acid (3450 cm−1), alkene (3050 cm−1), and carbonyl (1720 cm−1) functionalities. Nuclear magnetic resonance spectroscopy confirms its structure, with distinctive signals in the 1H NMR spectrum including the terminal methyl group at δ 0.68 ppm and alkene protons at δ 6.03 and 6.39 ppm. The 13C NMR spectrum shows key resonances for the carboxylic acid (174.4 ppm), alkene (132.6 and 125.9 ppm), and lactone carbonyl (168.2 ppm) carbons.
=== Ribo-Q === In 2010, the group of Jason W. Chin presented a further optimized version of the orthogonal ribosome. The Ribo-Q is a 16S rRNA optimized to recognize tRNAs, which have quadruplet anti-codons to recognize quadruplet codons, instead of the natural triplet codons. With this approach the number of possible codons rises from 64 to 256. Even accounting for a variety of stop codons, more than 200 different amino acids could potentially be encoded this way.
== Comparable incidents == During the 2003 invasion of Iraq, approximately 40 oil wells were set on fire in the Persian Gulf within Iraq by Iraqi forces, ostensibly to hinder the invasion. The Kuwait Wild Well Killers, who successfully extinguished 41 of the Kuwait oil well fires in 1991, used their experience to tackle blazes in the Iraqi Rumaila oilfields in 2003.
Sources: en.wikipedia.org
=== Plays === Habis, tragédie (1714) Cléarque, tyran d'Héraclée, tragédie (1733 - English translation: Cléarchus, Tyrant of Heraclea, a tragedy) Marsidie reine des Cimbres, tragédie (1735 - English translation: Marsidie, Queen of the Cimbri) Semiramis, tragédie (1737 - English translation: Semiramis, tragedy)
An intraarticular fracture is a bone fracture that typically runs parallel to the joint surface in which the break crosses into the surface of a joint, through the articular cartilage. This always results in damage to the cartilage, an area of limited healing capability. Compared to extraarticular fractures, intraarticular have a higher risk for developing long-term complications, such as posttraumatic osteoarthritis. For the majority of these fractures, anatomic reduction is vital to maintain the integrity of the joint surface.
RNAi is an RNA-dependent gene silencing process that is controlled by RISC and is initiated by short double-stranded RNA molecules in a cell's cytoplasm, where they interact with the catalytic RISC component Argonaute. When the dsRNA is exogenous (coming from infection by a virus with an RNA genome or laboratory manipulations), the RNA is imported directly into the cytoplasm and cleaved to short fragments by Dicer. The initiating dsRNA can also be endogenous (originating in the cell), as in pre-microRNAs expressed from RNA-coding genes in the genome. The primary transcripts from such genes are first processed to form the characteristic stem-loop structure of pre-miRNA in the nucleus, then exported to the cytoplasm. Thus, the two dsRNA pathways, exogenous and endogenous, converge at the RISC. Exogenous dsRNA initiates RNAi by activating the ribonuclease protein Dicer, which binds and cleaves dsRNAs in plants, or short hairpin RNAs (shRNAs) in humans, to produce double-stranded fragments of 20–25 base pairs with a 2-nucleotide overhang at the 3′ end. Bioinformatics studies on the genomes of multiple organisms suggest this length maximizes target-gene specificity and minimizes non-specific effects. These short double-stranded fragments are called siRNAs. These siRNAs are then separated into single strands and integrated into an active RISC, by RISC-Loading Complex (RLC). RLC includes Dicer-2 and R2D2, and is crucial to unite Ago2 and RISC.
=== Other functions === Cholesterol translocation from outer to the inner mitochondrial membrane Activates mitochondrial cholesterol side-chain cleavage Import protein into mitochondrial matrix Anticoagulant function Modulates α-synuclein - malfunction of this process is thought to be a cause of Parkinson's disease.
Sources: en.wikipedia.org
Steve Biko (They Fought for Freedom). Maskew Miller Longman. ISBN 978-0-636-01660-6. Tutu, Desmond (1996). The Rainbow People of God. Image. ISBN 978-0-385-48374-2. Van Wyk, Chris (2007). We Write What We Like: Celebrating Steve Biko. Wits University Press. ISBN 978-1-86814-464-8. Wa Thingo, Ngugi (2009). Something Torn and New: An African Renaissance. Basic Civitas Books. ISBN 978-0-465-00946-6. Wiwa, Ken (2001). In the Shadow of a Saint: A Son's Journey to Understand His Father's Legacy. Steerforth. ISBN 978-1-58642-025-3. Woods, Donald (2004). Rainbow Nation Revisited: South Africa's Decade of Democracy. Andre Deutsch. ISBN 978-0-233-00052-7.
Properdin promotes phagocytosis of apoptotic T cells in two ways. One way is through binding to apoptotic T cells, which initiates AP-mediated C3b deposition, promoting cell uptake through CR3-bearing phagocytes. Another way is through properdin binding on T cells and directly mediating phagocytes. Properdin contains abilities to eliminate apoptotic cells in order to reduce harmful inflammatory and autoimmune reactions. Additionally, properdin binds malignant T cell lines, therefore, properdin deficiency may be a risk in the development of specific T cell malignancies. The alternative pathway is not dependent on antibodies. This branch of the complement system is activated by IgA immune complexes and bacterial endotoxins, polysaccharides, and cell walls, and results in producing anaphylatoxins, opsonins, chemotactic factors, and the membrane attack complex, all of which help fight pathogens.
In other instances, molecular interactions between gas molecules previously adsorbed on a solid surface form significant interactions with gas molecules in the gaseous phases. Hence, adsorption of gas molecules to the surface is more likely to occur around gas molecules that are already present on the solid surface, rendering the Langmuir adsorption isotherm ineffective for the purposes of modelling. This effect was studied in a system where nitrogen was the adsorbate and tungsten was the adsorbent by Paul Kisliuk (1922–2008) in 1957. To compensate for the increased probability of adsorption occurring around molecules present on the substrate surface, Kisliuk developed the precursor state theory, whereby molecules would enter a precursor state at the interface between the solid adsorbent and adsorbate in the gaseous phase. From here, adsorbate molecules would either adsorb to the adsorbent or desorb into the gaseous phase. The probability of adsorption occurring from the precursor state is dependent on the adsorbate's proximity to other adsorbate molecules that have already been adsorbed. If the adsorbate molecule in the precursor state is in close proximity to an adsorbate molecule that has already formed on the surface, it has a sticking probability reflected by the size of the SE constant and will either be adsorbed from the precursor state at a rate of kEC or will desorb into the gaseous phase at a rate of kES.
=== Bond specificity === Bond specificity, unlike group specificity, recognizes particular chemical bond types. This differs from group specificity, as it is not reliant on the presence of particular functional groups in order to catalyze a particular reaction, but rather a certain bond type (for example, a peptide bond).
=== Choice of ionization source === APCI generally suffers less ion suppression than ESI, as discussed previously. Where possible, if ion suppression is unavoidable it may be advisable to switch from ESI to APCI. If this is not possible, it may be useful to switch the ESI ionisation mode from positive to negative. Since fewer compounds are ionisable in negative ionisation mode, it is entirely possible that the ion suppressing species may be removed from the analysis. However, it should also be considered that the analyte of interest may not be ionised effectively in negative mode either, rendering this approach useless.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.